Confido Health has secured $10 million in Series A funding to expand its AI-powered voice agent platform that's reimagining how patients interact with healthcare providers over the phone.
The round, led by Blume Ventures with participation from Schema Ventures, Vicus Ventures, and existing investors Together Fund, DeVC, and Medmountain Ventures, brings the company's total funding to $13 million.
What is Confido Health?
Founded by serial entrepreneurs Chetan Reddy (CEO) and Vichar Shroff (CPO), Confido Health is tackling one of healthcare's most persistent pain points: the phone system. Despite digital advances, 81% of patients still call their providers, often facing long hold times, confusing phone trees, and days-long callback waits.
The New York-based startup's AI voice agents answer on the first ring, authenticate callers, and resolve requests ranging from appointment scheduling to prescription refills, insurance verification, and payment processing—all while documenting interactions directly in the electronic health record (EHR).
Funding Overview
| Funding Round | Amount | Lead Investors | Date | Valuation |
|---|---|---|---|---|
| Series A | $10M | Blume Ventures | Sept 2025 | Undisclosed |
| Seed | $3M | Together Fund | Dec 2024 | Undisclosed |
| Total Funding | $13M |
👉 Key Investors: Blume Ventures, Together Fund, Schema Ventures, Vicus Ventures, DeVC, Medmountain Ventures, plus strategic operators from Innovaccer and Memora Health
Why This Investment Signals a Healthcare Shift?
The timing of this investment reflects a critical inflection point in healthcare operations. With staffing shortages reaching crisis levels and patient demand surging, traditional phone-based access systems are breaking down.
Confido's platform stands out by handling comprehensive workflows beyond basic scheduling—a key differentiator in an increasingly crowded voice AI market.
The company reports 10x growth over eight months, now serving over 1 million patients compared to 150,000 in December 2024.
For private equity-backed healthcare groups and multi-site operators, Confido's unified platform offers compelling economics.
With automation rates exceeding 80% and the ability to consolidate patient access across dozens of locations, the ROI potential is significant.
At Dallas Renal Group, implementation cut inbound wait times from minutes to 15 seconds while saving staff nearly 50 hours weekly.
AiCurator Rating: 8/10
Confido's comprehensive approach to healthcare communication positions it well to become the infrastructure layer for patient access, particularly as consolidation accelerates across specialty practices.
Quick FAQs
Who led Confido Health's Series A round?
Blume Ventures led the $10 million round, with participation from Schema Ventures, Vicus Ventures, and existing investors.
What makes Confido different from other healthcare AI companies?
Unlike competitors focused solely on appointment scheduling, Confido handles comprehensive workflows including refills, payments, referrals, and care coordination—all integrated with existing EHR systems.
How many patients does Confido currently serve?
The platform now provides 24/7 access to over 1 million patients across 15+ healthcare organizations with 50+ locations.
The Road Ahead for Confido Health
With fresh capital in hand, Confido plans to expand beyond its current specialties—pediatrics, orthopedics, nephrology, and dermatology—into recalls, reactivation workflows, and complex care coordination.Â
The company's vision extends beyond fixing broken phone systems to becoming the standard infrastructure for all patient communication.
Source
